Association of patient and disease characteristics with outcomes of regorafenib in patients with metastatic colorectal cancer.

被引：0
|
作者：
Hsieh, Ronan Wenhan
Lee, Matthew
Johnson, Devin
Zhang, Chenxin
Moon, Jee-Young
Hsu, Dennis
Acuna-Villaorduna, Ana
Kuang, Chaoyuan
机构：
[1] Univ Pittsbugh, Med Ctr, Pittsburgh, PA USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
135
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [21] Regorafenib in the treatment of metastatic colorectal cancer
    de la Fouchardiere, Christelle
    FUTURE ONCOLOGY, 2018, 14 (22) : 2239 - 2246
  • [22] Regorafenib: A Review in Metastatic Colorectal Cancer
    Sohita Dhillon
    Drugs, 2018, 78 : 1133 - 1144
  • [23] The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
    Yuki, S.
    Harada, K.
    Kawakami, T.
    Ogata, T.
    Hu, Q.
    Fushiki, K.
    Oshima, K.
    Kadowaki, S.
    Taniguchi, H.
    Muro, K.
    Nakanishi, R.
    Ando, K.
    Nambara, S.
    Nakamura, T.
    Kawamoto, Y.
    Komatsu, Y.
    Oki, E.
    Masuishi, T.
    Yamazaki, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S441 - S442
  • [24] The role of regorafenib in metastatic colorectal cancer
    Riechelmann, Rachel
    Grothey, Axel
    LANCET ONCOLOGY, 2015, 16 (06): : 596 - 597
  • [25] Regorafenib in Metastatic Colorectal Cancer: Optimal Dosing and Patient Selection Recommendations
    Grothey, Axel
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 514 - 517
  • [26] Regorafenib approved in Metastatic Colorectal cancer
    Andre, Thierry
    Dumont, Sarah N.
    BULLETIN DU CANCER, 2013, 100 (10) : 1027 - 1029
  • [27] TDM of Regorafenib in patients with metastatic colorectal cancer: preliminary results
    Beinse, G.
    Khoudour, N.
    Joly, C.
    Tournigand, C.
    Rousseau, B.
    Hulin, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 44 - 45
  • [28] Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events
    Hofheinz, Ralf-Dieter
    Arnold, Dirk
    Kubicka, Stefan
    Prasnikar, Nicole
    Vogel, Arndt
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (06) : 300 - 308
  • [29] Clinical and economic outcomes of pegfilgrastim in metastatic colorectal cancer.
    Wilfong, Lalan S.
    Garey, Jody S.
    He, Bo
    Hayes, Jad
    Ives, Hope
    Hoang, Susan Nga
    Neubauer, Marcus A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Mitani, Seiichiro
    Hasegawa, Hiroko
    Narita, Yukiya
    Kadowaki, Shigenori
    Ura, Takashi
    Ando, Masashi
    Mori, Keita
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345